Evidence map›Paper›PMID 30820753›Full record

ArticleHepatology international2019

Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study.

Tatsuya Ide, Hironori Koga, Masahito Nakano, Satoru Hashimoto, Hiroshi Yatsuhashi, Nobito Higuchi, Makoto Nakamuta, Satoshi Oeda, Yuichiro Eguchi, Satoshi Shakado and 17 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Hepatology international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 3 pooled it
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 14 institutions in 1 country.

Tatsuya IdeDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan.
Hironori KogaDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan. hirokoga@med.kurume-u.ac.jp.ORCID http://orcid.org/0000-0001-5814-9543
Masahito NakanoDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan.
Satoru HashimotoClinical Research Center, National Hospital Organization Nagasaki Medical Center, 2-1001-1 Kubara, Omura, 856-8562, Japan.
Hiroshi YatsuhashiClinical Research Center, National Hospital Organization Nagasaki Medical Center, 2-1001-1 Kubara, Omura, 856-8562, Japan.
Nobito HiguchiDivision of Gastroenterology, National Kyusyu Medical Center Hospital, 1-8-1 Chigyouhama, Chuou-ku, Fukuoka, 810-8563, Japan.
Makoto NakamutaDivision of Gastroenterology, National Kyusyu Medical Center Hospital, 1-8-1 Chigyouhama, Chuou-ku, Fukuoka, 810-8563, Japan.
Satoshi OedaLiver Center, Saga University Hospital, 5-1-1 Nabeshima, Saga, 849-8501, Japan.
Yuichiro EguchiLiver Center, Saga University Hospital, 5-1-1 Nabeshima, Saga, 849-8501, Japan.
Satoshi ShakadoDepartment of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan.
Shotaro SakisakaDepartment of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan.
Yoko YoshimaruDepartment of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan.
Yutaka SasakiDepartment of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan.
Yuichi HonmaThird Department of Internal Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8556, Japan.
Masaru HaradaThird Department of Internal Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8556, Japan.
Masataka SeikeDepartment of Gastroenterology, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hazama-machi, Yufu, 879-5593, Japan.
Tatsuji MaeshiroFirst Department of Internal Medicine, Faculty of Medicine, University of the Ryukyus, 207 Azauehara, Nishihara-machi, Nakagashira-gun, 903-0215, Japan.
Satoshi MiumaDepartment of Gastroenterology and Hepatology, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 850-0000, Japan.
Kazuhiko NakaoDepartment of Gastroenterology and Hepatology, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 850-0000, Japan.
Seiichi MawatariDigestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1, Sakuragaoka, 890-8544, Kagoshima, Japan.
Akio IdoDigestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1, Sakuragaoka, 890-8544, Kagoshima, Japan.
Kenji NagataDepartment of Liver Disease, University of Miyazaki Hospital, 5200 Kihara, Kiyotake-machi, Miyazaki, 889-1692, Japan.
Shuichi MatsumotoFukuoka Tokushukai Medical Center, 4-5 Sugukita, Kasuga, 816-0864, Japan.
Yuko TakamiDepartment of Hepato-Biliary-Pancreatic Surgery and Clinical Research Institute, National Kyushu Medical Center Hospital, 1-8-1 Chigyouhama, Chuou-ku, Fukuoka, 810-8563, Japan.
Tetsuo SohdaHepatology Division, Japanese Red Cross Fukuoka Hospital, 3-1-1 Okusu, Minami-ku, Fukuoka, 815-8555, Japan.
Tatsuyuki KakumaBiostatistics Center, Kurume University, 67 Asahi-machi, Kurume, 830-0011, Japan.
Takuji TorimuraDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan.
Kurume University · JPFukuoka University · JPKagoshima University · JPKumamoto University · JPNagasaki Medical Center · JPNagasaki University Hospital · JPSaga University · JPUniversity of Occupational and Environmental Health Japan · JPFukuoka Tokushukai Hospital · JPJapanese Red Cross Fukuoka Hospital · JPNational Kyushu Medical Center · JPOita University · JPUniversity of Miyazaki · JPUniversity of the Ryukyus · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhile achieving sustained virological response (SVR) following interferon-based or direct-acting antiviral agent (DAA) treatments reduces the incidence of hepatocellular carcinoma (HCC), an increase in unexpected early occurrence or recurrence of HCC after hepatitis C virus elimination by DAA treatments has been reported. We prospectively investigated the incidence and risk factors of HCC after DAA treatment in a large multicenter cohort in Japan.

methodsPatients with chronic hepatitis C with or without cirrhosis who were treated with DAAs and obtained SVR were enrolled. DAAs were administered for 3 or 6 months. A total of 2552 patients were enrolled.

resultsOf these, 70 patients (2.7%) developed HCC. The 12-, 24-, and 36-month cumulative HCC incidences were 1.3%, 2.9%, and 4.9% in all patients; 2.5%, 5.2%, and 10.0% in those with cirrhosis; and 0.9%, 2.1%, and 2.9% in those without cirrhosis, respectively. Multivariate analysis revealed age, sex, gamma-glutamyl transpeptidase level, and fibrosis-4 index to be independent factors associated with HCC. Patients with these four factors had an approximately six-to-sevenfold increased risk for HCC development. Five patients with large and early tumor occurrence did not receive contrast imaging examinations before treatment.

conclusionAlthough the results of our prospective study suggested that achieving SVR by DAA treatment reduces the incidence of HCC, HCC development still occurs. Careful follow-up is important in patients with risk factors.

Indexed as

AdultAgedAged, 80 and overAntiviral AgentsCarcinoma, HepatocellularCohort StudiesFemaleHepatitis C, ChronicHumansIncidenceInterferonsJapanLiver NeoplasmsMaleMiddle AgedProspective StudiesAntiviral AgentsInterferonsFibrosis-4 (FIB-4) indexHepatitis C virusHepatocarcinogenesisSustained virological response

Identifiers

PMID30820753
OpenAlexW2917202881

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.